Short Interest in Silexion Therapeutics Corp (NASDAQ:SLXN) Rises By 20.7%

Silexion Therapeutics Corp (NASDAQ:SLXN) was the recipient of a large increase in short interest during the month of February. As of February 13th, there was short interest totaling 55,759 shares, an increase of 20.7% from the January 29th total of 46,202 shares. Currently, 1.9% of the company’s shares are sold short. Based on an average daily volume of 33,262 shares, the days-to-cover ratio is presently 1.7 days. Based on an average daily volume of 33,262 shares, the days-to-cover ratio is presently 1.7 days. Currently, 1.9% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Several research firms have commented on SLXN. Zacks Research raised shares of Silexion Therapeutics to a “hold” rating in a research note on Tuesday, December 16th. Litchfield Hills Research started coverage on shares of Silexion Therapeutics in a report on Monday, December 15th. They set a “buy” rating on the stock. Finally, Wall Street Zen lowered shares of Silexion Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $75.00.

Silexion Therapeutics Stock Performance

Shares of Silexion Therapeutics stock opened at $1.68 on Friday. The company has a market capitalization of $5.27 million, a PE ratio of -0.15 and a beta of -0.04. The company has a 50-day simple moving average of $1.87 and a two-hundred day simple moving average of $3.20. Silexion Therapeutics has a one year low of $1.42 and a one year high of $22.36. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.97 and a current ratio of 3.97.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.